Adage Capital Partners Gp, L.L.C. Ascendis Pharma A/S Transaction History

Adage Capital Partners Gp, L.L.C.

$56.4 Billion
Q2 2025

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 459,606 shares of ASND stock, worth $96.9 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

459,606

Previous 327,405 40.38%

Holding current value

$96.9 Million

Previous $51 Million 55.45%

% of portfolio

0.14%

Previous 0.1%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$137.41 - $179.1 $18.2 Million - $23.7 Million	132,201 Added 40.38%	459,606 $79.3 Million
Q1 2025 May 15, 2025	BUY	$119.49 - $168.84 $39.1 Million - $55.3 Million	327,405 New	327,405 $51 Million
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $37.7 Million - $51.2 Million	-333,555 Reduced 40.65%	486,957 $72.7 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $74 Million - $93.9 Million	611,000 Added 291.63%	820,512 $112 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $8.09 Million - $10.4 Million	65,512 Added 45.49%	209,512 $31.7 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $32.9 Million - $48.7 Million	-382,371 Reduced 72.64%	144,000 $18.1 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $14.1 Million - $16.9 Million	-162,629 Reduced 23.6%	526,371 $49.3 Million
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $13.2 Million - $18.5 Million	189,000 Added 37.8%	689,000 $61.5 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $14.7 Million - $17.7 Million	-140,000 Reduced 21.88%	500,000 $53.6 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $40.8 Million - $54.1 Million	410,000 Added 178.26%	640,000 $78.2 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $5.46 Million - $7.16 Million	65,000 Added 39.39%	230,000 $23.8 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $546,560 - $823,270	-7,000 Reduced 4.07%	165,000 $15.3 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $12.5 Million - $16.6 Million	122,000 Added 244.0%	172,000 $20.2 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $6.36 Million - $8.48 Million	50,000 New	50,000 $6.73 Million
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $4.03 Million - $4.63 Million	-30,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $1.11 Million - $1.56 Million	-10,000 Reduced 25.0%	30,000 $4.44 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $14.6 Million - $22.3 Million	-160,000 Reduced 80.0%	40,000 $5.57 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $4.79 Million - $5.95 Million	-50,000 Reduced 20.0%	200,000 $19.3 Million
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $2.68 Million - $3.3 Million	25,000 Added 11.11%	250,000 $28.8 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $6.22 Million - $13 Million	-100,000 Reduced 30.77%	225,000 $26.5 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $4.14 Million - $5.23 Million	75,000 Added 30.0%	325,000 $20.4 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $1.59 Million - $1.91 Million	25,000 Added 11.11%	250,000 $17.7 Million
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $20.5 Million - $25.9 Million	-350,000 Reduced 60.87%	225,000 $15 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $21.7 Million - $37.8 Million	556,000 Added 2926.32%	575,000 $37.6 Million
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $607,620 - $767,220	19,000	19,000 $761,000

Others Institutions Holding ASND

# of Institutions

276

Shares Held

60M

Call Options Held

217K

Put Options Held

73.3K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.8B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Ascendis Pharma A/S Transaction History